BIAF vs MXCT: stock comparison and AI forecast
Bioaffinity Technologies, Inc. (BIAF) and Maxcyte, Inc. (MXCT) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BIAF Bioaffinity Technologies, Inc.
- Price
- $2.60 -91.8% · 6M
- Market Cap
- $3M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
MXCT Maxcyte, Inc.
- Price
- $1.26 +44.5% · 6M
- Market Cap
- $130M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- MXCT is 38.9 times larger than BIAF by market capitalization ($130M against $3M).
- Over the last six months MXCT returned +44.5% and BIAF -91.8%.
- MXCT turns -114.8% of its revenue into net income, against -257.3% for BIAF.
- BIAF carries 1.02 times debt per unit of equity, against 0.16 times for MXCT.
- Both companies share the SEC industry classification Services-Commercial Physical & Biological Research.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BIAF | MXCT |
|---|---|---|
| Market Cap | $3M | $130M |
| P/B Ratio | 0.89x | 0.82x |
| EPS | $-9.13 | $-0.38 |
| Book Value/Share | $2.93 | $1.54 |
| Revenue/Share | $4.59 | $0.30 |
| FCF/Share | $-9.00 | $-0.23 |
Profitability & Margins
| Metric | BIAF | MXCT |
|---|---|---|
| ROE | -402.9% | -22.4% |
| ROA | -199.3% | -19.3% |
| ROIC | – | -23.9% |
| Gross Margin | – | 79.2% |
| Operating Margin | -209.8% | -134.6% |
| Net Margin | -257.3% | -114.8% |
| EBT Margin | -257.2% | -114.8% |
| Tax Rate | -0.3% | – |
Financial Health
| Metric | BIAF | MXCT |
|---|---|---|
| Current Ratio | 1.44x | 12.26x |
| Quick Ratio | 1.41x | 11.47x |
| D/E Ratio | 1.02x | 0.16x |
| Financial Leverage | 2.02x | 1.16x |
| Interest Coverage | -249.2x | -818.0x |
| Working Capital | $1M | $111M |
Cash Flow
| Metric | BIAF | MXCT |
|---|---|---|
| Operating Cash Flow | -$11M | -$23M |
| Free Cash Flow | -$12M | -$24M |
| Capital Spending | -$90K | -$670K |
| FCF/Sales | -195.9% | -76.1% |
| CapEx/Sales | 1.6% | 2.1% |
Operational Efficiency
| Metric | BIAF | MXCT |
|---|---|---|
| Asset Turnover | 0.77x | 0.17x |
| Receivables Turnover | – | 7.9x |
| Inventory Turnover | – | 0.8x |
| Fixed Assets Turnover | 18.8x | 2.1x |
| Days Sales Outstanding | – | 46 days |
| Days Inventory | – | 441 days |
| Payables Period | – | 98 days |
| Cash Conversion Cycle | – | 389 days |
Income Statement
| Metric | BIAF | MXCT |
|---|---|---|
| Total Revenue | $6M | $31M |
| Operating Income | -$12M | -$42M |
| Net Income | -$15M | -$36M |
| R&D Expense | $1M | $17M |
| SG&A Expense | $11M | $47M |
| Cost of Goods Sold | – | $6M |
Dividend & Shareholder Information
| Metric | BIAF | MXCT |
|---|---|---|
| Shares Outstanding | 1M | 103M |
BIAF vs MXCT: stock comparison and AI forecast
Which is bigger, BIAF or MXCT?
MXCT is 38.9 times larger than BIAF by market capitalization ($130M against $3M).
Which stock performed better over the last six months, BIAF or MXCT?
Over the last six months MXCT returned +44.5% and BIAF -91.8%.
Which one does Intratio's AI model rank higher, BIAF or MXCT?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.